Marco Roccato’s Post

Review the exciting content presented at #EHA2024. Catch up with our live social media relating to longer-term follow-up, patient outcomes, and real-world findings in multiple myeloma, here: https://loom.ly/MqS2Ex0 #myeloma #mmsm

For #ClinicalResearch teams seeking to expand and extend their impact, patient organizations can be an impactful avenue for advancing progress, explains IQVIA. Check out three ways that patient organizations can advance scientific and clinical progress and help to educate and support patients: https://bit.ly/4ggFjum

How can we optimise treatments for our patients and maximise outcomes? In this 5 minute video Prof. Gerald Prager delves into the late-stage alternatives for long-term management of advanced CRC, including 3rd line and beyond. Catch the video and downloadable resources here https://ow.ly/KsTe50R6CS3. #MedEd

View the ‘Best Practice Exchange in Clinical Case Scenarios’ program to listen to experts in the field discussing the latest evidence supporting the use of new therapies in clinical practice. https://lnkd.in/davDGh5t

BOPA Member Jessica Keen is inviting UK oncology healthcare professionals to share your views on Pharmacogenomic testing for people being treated for cancer ✅ 🏥 https://lnkd.in/e9Aw7Dyh   “Pharmacogenomic testing has the potential to optimise a person’s medicines and avoid the risk of harmful side effects. People with cancer are regularly started on multiple medicines to treat their cancer, the symptoms of cancer and the effects of treatment. 💊 💉 The routine DPYD testing that is available for cancer patients across the NHS is an exemplar of how pgx can be implemented within pathways to improve patient care.   But what if patients could be tested for multiple genes at once using a pharmacogenomic panel, instead of just one gene at a time?   In my pre-doctoral fellowship I’m uncovering more about how we measure the outcomes of pharmacogenomic panel testing for people with cancer, and what the public think about including this in cancer care.   I also want to get the views of the healthcare professionals who might deliver this service: https://lnkd.in/e9Aw7Dyh How would panel testing fit within existing cancer care pathways? Which patient groups might benefit most from testing? Who should deliver this service in oncology settings and how might the information be used to inform prescribing? If you are a UK based doctor / pharmacist / nurse/ advanced practitioner working in oncology please visit this link to share your views and help to inform future studies in this area.” https://lnkd.in/e9Aw7Dyh

Please take the survey:

Interesting study from oncologists at Healthcare Global Hospitals reveals the correlation between fluoride and OSMF, a pre-cancerous condition. Gutka and Pan Masala, commonly consumed in India, contain high levels of fluoride. This highlights the need for more clinical studies in India to understand the impact of fluoride on public health. The DPDPA ACT provisions can help create an ecosystem for further research and lead to better clinical outcomes. Check out the groundbreaking study here: https://lnkd.in/gPhk9R4G

🗓 Save the Date: December 17th Join us for our upcoming webinar as we explore the achievements, innovations, and real-world clinical benefits of RetinAI Discovery®. We are honored to host esteemed experts, Prof. Paulo Eduardo Stanga and Dr. Francisco Cabrera López, who will share their insights and experiences. What to Expect: 1️⃣ Highlights of RetinAI’s 2024 achievements 2️⃣ A sneak peek at exciting new features to RetinAI Discovery, including: - Automated data uploads to simplify data management - Our AI-powered SEARCH engine for faster patient identification based on biomarker criteria - SMART Alarm Notifications to flag key patient characteristics for efficient monitoring 3️⃣ Real-world insights from physicians using RetinAI Discovery® Join us to see how RetinAI Discovery® is transforming retinal disease management with cutting-edge tools for OCT analysis, fluid tracking, and multimodal data integration. Register now 👉 https://lnkd.in/eQvcsP_D

Chatbots can generate quality, empathetic, and readable responses to patient questions comparable to physician responses sourced from an online forum, suggests equivalence study. https://ja.ma/3LzbDuQ

I’m thrilled to share this insightful article in which, together with industry peers (Thomas Metcalfe Stefan Schwoch) and #EFPIA we highlight the progress being made in advancing clinical trials for European patients. As the healthcare landscape evolves, it’s crucial that we continuously strive to improve access to innovative treatments and therapies. In the past, many breakthrough treatments for cancer, cardiovascular diseases, infectious diseases, and neurological conditions among others were researched, developed and introduced in Europe. However, this proud legacy is fading. Just 25 years ago, every second new treatment originated in Europe. Today, that number has dwindled to less than one in every five. The initiatives outlined in the article showcase a collaborative effort to streamline processes, enhance transparency, and prioritize patient-centricity in clinical trials. By leveraging digital technologies, fostering cross-sector partnerships, and promoting regulatory innovation, we can accelerate the development and delivery of life-changing therapies to those who need them most.   Daily, our efforts in clinical trials are shaping the future of medicine. I am truly committed to this research that is transforming healthcare and offering hope to countless individuals and families.    I encourage you to read the full article and join us in our mission to innovate healthcare for everyone’s benefit. Together, we can make a difference. Advancing Clinical Trials for European Patients: https://lnkd.in/egiZQppK #TeamBayer #ICTD2024 #WeWontRest #DIA #Regulatoryaffairs #HealthcareInnovation #ClinicalTrials #PatientCentricity #HealthForAll   Stefan Oelrich Christian Rommel Christoph Koenen Katarina Nedog